Abstract
In this issue of Cell Metabolism, Pirinen etal. (2020) show that disruption in NAD+ homeostasis is a key component of the pathogenesis of mitochondrial myopathy in humans that can be targeted by the administration of the NAD+ precursor niacin, identifying NAD+ boosting as a potential treatment for this devastating disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have